Thus, mutant KRAS plays a major role in TAZ expression and cancer stem self-renewal in pancreatic cancer cells, and ICMT has potential as a pharmacological target in the treatment of mutant KRAS pancreatic cancer cells (81). This evidence concerns the gene KRAS and familial pancreatic carcinoma.